Strength Training During Cancer Survivorship: Evidence, Mechanisms, and Clinical Implications

Abstract

Cancer survivorship has emerged as a significant focus in oncology, given the rising number of individuals living beyond a cancer diagnosis. Strength training, as a component of physical rehabilitation, is receiving considerable attention for its multifaceted benefits in this population. This review synthesizes the epidemiology, pathophysiological mechanisms, risk factors, clinical features, diagnostic considerations, and therapeutic modalities pertaining to strength training during cancer survivorship. Highlighting recent advances, clinical guidelines, and current controversies, the article provides a comprehensive, evidence-based perspective for healthcare professionals managing cancer survivors.

Introduction

The increasing prevalence of cancer survivors, due to advances in early detection and therapeutic modalities, necessitates a shift in focus from acute care to long-term survivorship management. Cancer survivors are at risk for a spectrum of late effects, including fatigue, sarcopenia, functional decline, and psychological distress. Strength training, or resistance exercise, has emerged as a cornerstone intervention to address these sequelae. This article reviews the scientific underpinnings, clinical relevance, and practical implementation of strength training in cancer survivorship, drawing from recent guidelines and research evidence to inform multidisciplinary care.

Epidemiology / Disease Burden

Globally, the population of cancer survivors is projected to surpass 22 million by 2030. Survivors often experience persistent physical impairments, with up to 75% reporting reduced muscle strength and functional limitations. Sarcopenia and cachexia are particularly prevalent in survivors of solid tumors and hematological malignancies, contributing to frailty, increased healthcare utilization, and diminished quality of life. The economic burden associated with survivorship care underscores the need for cost-effective, scalable interventions such as exercise-based rehabilitation programs.

Pathophysiology

Cancer and its treatments including chemotherapy, radiation, hormonal therapy, and surgery induce a cascade of pathophysiological changes. These include systemic inflammation, mitochondrial dysfunction, hormonal imbalances, and direct myotoxic effects, all contributing to muscle atrophy and decreased neuromuscular function. Strength training counteracts these mechanisms by promoting muscle protein synthesis, enhancing mitochondrial biogenesis, and modulating inflammatory cytokine profiles. Mechanistically, resistance exercise activates the mTOR pathway, crucial for muscle regeneration and metabolic homeostasis, providing a biological rationale for its integration into survivorship care.

Risk Factors

Risk factors for functional decline and poor musculoskeletal outcomes in cancer survivors include older age, pre-existing comorbidities (e.g., diabetes, cardiovascular disease), advanced cancer stage, aggressive treatment regimens, and sedentary lifestyle. Genetic predispositions, nutritional deficiencies, and psychosocial stressors further modulate vulnerability. Identifying high-risk individuals enables personalized exercise prescriptions, optimizing safety and therapeutic efficacy.

Clinical Features

Common clinical manifestations addressed by strength training include cancer-related fatigue, muscle weakness, impaired balance, reduced gait speed, and decreased bone mineral density. Survivors may also present with lymphedema, neuropathy, and arthralgia, conditions that can be mitigated by tailored resistance programs. Psychologically, improved muscle strength correlates with enhanced mood, reduced anxiety, and improved self-efficacy, further supporting the holistic benefits of strength-based interventions.

Diagnosis

Assessment of cancer survivors prior to initiating strength training should encompass a comprehensive evaluation of physical function, including muscle strength testing (e.g., handgrip dynamometry, sit-to-stand tests), assessment of activities of daily living, and risk stratification for exercise-induced adverse events. Laboratory workup may include evaluation of inflammatory markers, nutritional status, and, where indicated, bone density scans. Collaboration with physiatrists, physiotherapists, and oncologists ensures a safe and individualized approach to exercise initiation.

Treatment & Management

Strength training protocols for cancer survivors are best individualized, typically involving 2-3 sessions per week, targeting major muscle groups with progressive overload principles. Modalities include free weights, resistance bands, and machine-based exercises, with program adjustments based on tolerance, treatment phase, and specific contraindications. Supervised programs yield superior adherence and outcomes, although home-based protocols can be effective with adequate education and remote monitoring. Concurrent aerobic training may further augment gains in cardiorespiratory fitness and functional independence.

Recent Advances / Emerging Therapies

Recent research emphasizes the integration of precision medicine approaches in exercise prescription, including the use of wearable technology for real-time monitoring, tele-rehabilitation platforms, and genetic profiling to personalize exercise regimens. Novel interventions such as blood flow restriction training and neuromuscular electrical stimulation are being explored for survivors unable to engage in traditional resistance activities. Ongoing trials are evaluating the impact of combined nutritional and exercise interventions on muscle mass preservation and metabolic health in diverse cancer populations.

Guideline Recommendations

Major oncological societies, including the American College of Sports Medicine (ACSM) and the National Comprehensive Cancer Network (NCCN), endorse strength training as a core component of survivorship care. Guidelines recommend at least two sessions of moderate-intensity resistance exercise per week, with modifications based on comorbidities, treatment side effects, and functional status. Pre-exercise medical clearance is advised for survivors with uncontrolled comorbidities or high-risk features. Multidisciplinary collaboration and ongoing education of healthcare providers are critical for successful implementation and sustained patient engagement.

Conclusion

Strength training represents a safe, effective, and evidence-based intervention for improving functional outcomes, mitigating long-term sequelae, and enhancing quality of life in cancer survivors. Mechanistic insights and emerging technologies are driving personalized exercise medicine, while robust clinical guidelines support integration into standard survivorship care. Continued research is essential to refine protocols, optimize adherence, and expand access, ensuring that all survivors benefit from the restorative potential of resistance exercise.